edp-305
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 11, 2017 (NCT03187496)
Timeline
Indications
Mechanism of action
- Bile acid receptor FXRAGONIST
NR1H4 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- edp-305
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04378010 | Phase 2 | Jan 27, 2020 | Enanta Pharmaceuticals |
| NCT03783897 | Phase 1 | Nov 27, 2018 | Covance, Enanta Pharmaceuticals |
| NCT03748628 | Phase 1 | Oct 5, 2018 | Enanta Pharmaceuticals |
| NCT03610945 | Phase 1 | Jul 19, 2018 | Enanta Pharmaceuticals |
| NCT03421431 | Phase 2 | Apr 25, 2018 | Enanta Pharmaceuticals, ICON, Triangle Biostatistics |
| NCT03394924 | Phase 2 | Dec 27, 2017 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA), Triangle Biostatistics |
| NCT03187496 | Phase 1 | May 11, 2017 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals | For profit | 7 | 7 | 2 | 2017 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 2 | 0 | 2 | 2017 |
| Triangle Biostatistics | For profit | 2 | 0 | 1 | 2017 |
| Covance | For profit | 1 | 0 | 1 | 2018 |
| ICON | For profit | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1